Galectin-1 and -3 as biomarkers for capsular contracture. A pilot study

Galectin-1 and -3 as biomarkers for capsular contracture. A pilot study - Galectin-1 and -3 as biomarkers for capsular contracture

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44974

Enrollment

Registered

2015-05-01

Start date

2016-08-29

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

capsular contracture

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - females aged 18 or over - females who have developed capsular contracture (Baker score 1&2 and 3&4) after bilateral cosmetic breast augmentation with silicone breast implants at least one year after implant implantation - females who who are on the waiting list for a breast augmentation will serve as a control group

Exclusion criteria

Exclusion criteria: - females who have a co-morbidity (e.g. diseases of the liver, lung, heart, kidney, or skin); - females who have (a history of) cancer - females who have a capsular contracture for more than 5 years - females who have had silicone injections - females who are currently smoking or smoked in the past year

Design outcomes

Primary

Measure	Time frame
Serum and local Galectin-1, -3, HLA and IgE	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results